The impact of genetic factors on the response to migraine therapy
Author:
Tsirelis Daniil1, Tsekouras Alexandros1, Stamati Polyxeni1, Liampas Ioannis1ORCID, Zoupa Elli2, Dastamani Metaxia1, Tsouris Zisis1, Papadimitriou Anastasios3, Dardiotis Efthimios1, Siokas Vasileios4
Affiliation:
1. Department of Neurology, University Hospital of Larissa, Faculty of Medicine , University of Thessaly , 41110 Larissa , Greece 2. Larisa Day Care Center of People with Alzheimer’s Disease , Association for Regional Development and Mental Health (EPAPSY) , 15124 Marousi , Greece 3. General Hospital of Lamia , 35100 Lamia , Greece 4. Department of Neurology, University Hospital of Larissa, Faculty of Medicine , University of Thessaly , 41100 Larissa , Greece
Abstract
Abstract
Migraine is a multidimensional disease affecting a large portion of the human population presenting with a variety of symptoms. In the era of personalized medicine, successful migraine treatment presents a challenge, as several studies have shown the impact of a patient’s genetic profile on therapy response. However, with the emergence of contemporary treatment options, there is promise for improved outcomes. A literature search was conducted in PubMed and Scopus, in order to obtain studies investigating the impact of genetic factors on migraine therapy outcome. Overall, 23 studies were included in the current review, exhibiting diversity in the treatments used and the genetic variants investigated. Divergent genes were assessed for each category of migraine treatment. Several genetic factors were identified to contribute to the heterogeneous response to treatment. SNPs related to pharmacodynamic receptors, pharmacogenetics and migraine susceptibility loci were the most investigated variants, revealing some interesting significant results. To date, various associations have been recorded correlating the impact of genetic factors on migraine treatment responses. More extensive research needs to take place with the aim of shedding light on the labyrinthine effects of genetic variations on migraine treatment, and, consequently, these findings can promptly affect migraine treatment and improve migraine patients’ life quality in the vision of precise medicine.
Publisher
Walter de Gruyter GmbH
Reference107 articles.
1. Amiri, P., Kazeminasab, S., Nejadghaderi, S.A., Mohammadinasab, R., Pourfathi, H., Araj-Khodaei, M., Sullman, M.J.M., Kolahi, A.-A., and Safiri, S. (2022). Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front. Neurol. 12: 800605, https://doi.org/10.3389/fneur.2021.800605. 2. Asuni, C., Cherchi, A., Congiu, D., Piccardi, M.P., Del Zompo, M., and Stochino, M.E. (2007). Association study between clinical response to rizatriptan and some candidate genes. J. Headache Pain 8: 185–189, https://doi.org/10.1007/s10194-007-0388-5. 3. Atasayar, G., Eryilmaz, I.E., Karli, N., Egeli, U., Zarifoglu, M., Cecener, G., Taskapilioglu, O., Tunca, B., Yildirim, O., Ak, S., et al.. (2016). Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. J. Neurol. Sci. 366: 149–154, https://doi.org/10.1016/j.jns.2016.05.019. 4. Aynacioglu, A.S., Sachse, C., Bozkurt, A., Kortunay, S., Nacak, M., Schröder, T., Kayaalp, S.O., Roots, I., and Brockmöller, J. (1999). Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 66: 185–192, https://doi.org/10.1053/cp.1999.v66.100072001. 5. Barbanti, P., Fofi, L., Aurilia, C., and Egeo, G. (2013). Dopaminergic symptoms in migraine. Neurol. Sci. 34(Suppl. 1): S67–S70, https://doi.org/10.1007/s10072-013-1415-8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|